Patents by Inventor Mark Gelfand

Mark Gelfand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12251150
    Abstract: Neuromodulation cryotherapeutic devices and associated systems and methods are disclosed herein. A cryotherapeutic device configured in accordance with a particular embodiment of the present technology can include an elongated shaft having distal portion and a supply lumen along at least a portion of the shaft. The shaft can be configured to locate the distal portion intravascularly at a treatment site proximate a renal artery or renal ostium. The supply lumen can be configured to receive a liquid refrigerant. The cryotherapeutic device can further include a cooling assembly at the distal portion of the shaft. The cooling assembly can include an applicator in fluid communication with the supply lumen and configured to deliver cryotherapeutic cooling to nerves proximate the target site when the cooling assembly is in a deployed state.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: March 18, 2025
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Naomi Buckley, Benjamin J Clark, Michael Cummins, Danny Donovan, Mark Gelfand, Luke Hughes, Brian Kelly, Gary Kelly, Grace Kelly, John Kelly, Mark S. Leung, Gwenda Francis, Barry Mullins, Karun D. Naga, Stephen Nash, Eric Ryba, Fiachra Sweeney, Vincenzo Tilotta, Roman Turovskiy, Lana Woolley, Denise Zarins, Michael Turovskiy
  • Publication number: 20250082929
    Abstract: Examples of the disclosure include methods of implanting stimulation leads.
    Type: Application
    Filed: November 22, 2024
    Publication date: March 13, 2025
    Inventors: Randy W. Westlund, Mark Gelfand
  • Publication number: 20250082933
    Abstract: A system for treating disordered breathing of a human being includes an implantable transvenous stimulation lead having at least one stimulation electrode and a sensor configured to detect activity level of the human being. The system includes an energy source, a pulse generator and circuitry, the circuitry operative to receive a signal indicative of the activity level of the human being from the sensor, wherein the circuitry is configured to cause the energy source and the pulse generator to deliver spaced apart stimulation signals to the at least one stimulation electrode while the activity level of the human being is sufficiently low to be indicative of sleep. Spaced apart stimulation pulses from the electrode are configured to extend a duration of a time of at least one breath being defined as the time from an onset of inhalation to the onset of inhalation of a successive breath.
    Type: Application
    Filed: November 21, 2024
    Publication date: March 13, 2025
    Inventors: Mark Gelfand, Howard R. Levin, Andrew Halpert, Antonios Panteleon
  • Patent number: 12239839
    Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.
    Type: Grant
    Filed: August 9, 2023
    Date of Patent: March 4, 2025
    Assignee: BackBeat Medical, LLC
    Inventors: Howard Levin, Mark Gelfand
  • Patent number: 12239819
    Abstract: A apparatus and method to treat patients with acute decompensated heart failure (ADHF), heart failure or another fluid overload condition, that includes: administrating a diuretic to the patient to increase urine output of the patient; monitoring a rate or amount of urine output by the patient after administration of the diuretic; infusing a hydration liquid into the patient to induce an increase in the urine output; and adjusting the rate or amount of the hydration liquid infused into the patient to achieve a target fluid loss in the patient.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: March 4, 2025
    Assignee: Reprieve Cardiovascular, Inc.
    Inventors: Howard R. Levin, Andrew Halpert, Zoar Engelman, Mark Gelfand
  • Patent number: 12179014
    Abstract: A lead system and method of use for treating breathing disorders by the transvenous stimulation of the phrenic nerve.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: December 31, 2024
    Assignee: ZOLL RESPICARDIA, INC.
    Inventors: Randy W. Westlund, Mark Gelfand
  • Publication number: 20240278010
    Abstract: A means for treating breathing disorders by stimulating respiratory muscles or nerves to entrain respiratory systems while leaving respiratory drive intact. Embodiments of the invention employ frequency analysis to determine if appropriate stimulation energy is being applied.
    Type: Application
    Filed: December 12, 2023
    Publication date: August 22, 2024
    Inventors: Mark Gelfand, Kristofer J. James, Randy W. Westlund, Antonios Panteleon, Todd P. Goblish, Mark C. Lynn
  • Publication number: 20240252237
    Abstract: A method to treat a human patient including: advancing a catheter through a natural airway of the patient and positioning a distal portion of the catheter in the natural airway of a lung of the patient to a target region in the lung, injecting a conductive hypertonic saline solution having a concentration of at least 5% of sodium chloride by weight/volume from the distal portion of the catheter into the target region; delivering energy from the distal portion into the conductive hypertonic saline solution in the target region, wherein the energy heats the liquid in the portion of the airway, and ablating the target region with the heated liquid.
    Type: Application
    Filed: March 12, 2024
    Publication date: August 1, 2024
    Inventors: Dorin PANESCU, Shashank RAINA, Mark Gelfand, Mark LEUNG, Simplicio VELILLA
  • Publication number: 20240245455
    Abstract: Microwave catheter apparatuses, systems, and methods for achieving renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a catheter treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a microwave transmission element to a renal artery via an intravascular path. Renal neuromodulation may be achieved via dielectric heating in the presence of microwave irradiation that modulates neural fibers that contribute to renal function or alters vascular structures that feed or perfuse the neural fibers.
    Type: Application
    Filed: March 6, 2024
    Publication date: July 25, 2024
    Inventors: Karun D. Naga, Roman Turovskiy, Denise Zarins, Mark Gelfand, Arye Rosen
  • Publication number: 20240156521
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Application
    Filed: June 9, 2023
    Publication date: May 16, 2024
    Inventors: Dorin PANESCU, Andrew WU, Zoar Jacob ENGELMAN, Mark GELFAND, Mark S. LEUNG, Howard LEVIN
  • Patent number: 11974804
    Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: May 7, 2024
    Assignee: Medtronic Ireland Manufacturing Unlimited Company
    Inventors: Denise Zarins, Hanson Gifford, III, Mark E. Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Patent number: 11963718
    Abstract: Microwave catheter apparatuses, systems, and methods for achieving renal neuromodulation by intravascular access are disclosed herein. One aspect of the present application, for example, is directed to apparatuses, systems, and methods that incorporate a catheter treatment device comprising an elongated shaft. The elongated shaft is sized and configured to deliver a microwave transmission element to a renal artery via an intravascular path. Renal neuromodulation may be achieved via dielectric heating in the presence of microwave irradiation that modulates neural fibers that contribute to renal function or alters vascular structures that feed or perfuse the neural fibers.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: April 23, 2024
    Assignee: Medtronic Ireland Manufacturing Unlimited Company
    Inventors: Karun D. Naga, Roman Turovskiy, Denise Zarins, Mark Gelfand, Arye Rosen
  • Patent number: 11963714
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: April 23, 2024
    Assignee: Medtronic Ireland Manufacturing Unlimited Company
    Inventors: Mark E. Deem, Hanson S. Gifford, III, Denise Zarins, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
  • Publication number: 20240115310
    Abstract: A method to treat a human patient including: advancing a catheter through a natural airway of the patient and positioning a distal portion of the catheter in the natural airway of a lung of the patient to a target region in the lung, injecting a conductive hypertonic saline solution having a concentration of at least 5% of sodium chloride by weight/volume from the distal portion of the catheter into the target region; delivering energy from the distal portion into the hypertonic saline solution in the target region, wherein the energy heats the hypertonic saline solution in the target region; ablating the target region with the heated conductive hypertonic saline solution, sensing electric impedance or electric conductivity of the target region during the delivery of the energy, and controlling the rate or a bolus of the hypertonic saline solution injected into the target region based on the electric impedance or the electric conductivity.
    Type: Application
    Filed: October 16, 2023
    Publication date: April 11, 2024
    Inventors: Dorin Panescu, Shashank Raina, Simplicio Velilla, Mark Gelfand, Mark Leung
  • Patent number: 11925409
    Abstract: An ablation catheter configured to ablate tissue in a lung of a patient including: a flexible shaft that advances endobronchially into an airway of the lung and has an outer diameter of 2.0 mm or less; an ablation electrode attached to a distal portion of the flexible shaft and to deliver radiofrequency (RF) electrical current to the tissue and conductively connectable to an RF electrical energy source external to the patient; wherein an outer diameter of an assembly of the flexible shaft and the ablation electrode is no greater than 2.0 mm; a liquid outlet on the distal portion and configured to be in fluid communication with a source of hypertonic saline solution; and a first occluder attached to the flexible shaft proximal to the ablation electrode and proximal to the liquid outlet, wherein the first occluder is configured to expand to occlude the airway.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: March 12, 2024
    Assignee: ZIDAN MEDICAL INC.
    Inventors: Dorin Panescu, Shashank Raina, Mark Gelfand, Mark Leung, Simplicio Velilla
  • Publication number: 20240033517
    Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.
    Type: Application
    Filed: August 9, 2023
    Publication date: February 1, 2024
    Inventors: Howard Levin, Mark Gelfand
  • Patent number: 11883659
    Abstract: A means for treating breathing disorders by stimulating respiratory muscles or nerves to entrain respiratory systems while leaving respiratory drive intact. Embodiments of the invention employ frequency analysis to determine if appropriate stimulation energy is being applied.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: January 30, 2024
    Assignee: ZOLL RESPICARDIA, INC.
    Inventors: Mark Gelfand, Kristofer J. James, Randy W. Westlund, Antonios Panteleon, Todd P. Goblish, Mark C. Lynn
  • Publication number: 20240024682
    Abstract: Disclosed herein is a device, and method for treating heart failure by electrically modulating a splanchnic nerve with an implantable device.
    Type: Application
    Filed: February 21, 2023
    Publication date: January 25, 2024
    Inventors: Mark GELFAND, Tamara Colette BAYNHAM, Howard LEVIN
  • Patent number: 11864826
    Abstract: A method for treating a heart failure patient by ablating a nerve of the splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method including: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: January 9, 2024
    Assignee: Axon Therapies, Inc.
    Inventors: Howard Levin, Mark Gelfand
  • Publication number: 20230414871
    Abstract: A fluid therapy method for an ADHF patient includes setting a urine output rate desired threshold, setting one or more desired negative net gain rates, and optionally setting a total fluid loss goal. The urine output of the patient is monitored and fluid is automatically administered to the patient at increasing rates to equal to or approximately match the patient's increasing urine output rates until the patient's urine output rate reaches the set urine output rate desired threshold. Thereafter, fluid is administered to the patient at rates to achieve the set desired negative net gain rate until the fluid loss goal is reached. Thereafter, until the end of therapy, fluid is administered to the patient at rates equal to or approximately equal to the monitored urine output rates.
    Type: Application
    Filed: May 23, 2023
    Publication date: December 28, 2023
    Inventors: Andrew V. Halpert, Mark Tauscher, Mark Gelfand, Howard Levin